Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triplenex versus separate topical medications for open-angle glaucoma
RBR-6kkmskkNot yet recruiting
- Sponsor
- Centro Oftalmológico de Minas Gerais
- Start
- Jul 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of bimatoprost + brimonidine + timolol, travoprost, bimatoprost, timolol, dorzolamide and 2 more in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Centro Oftalmológico de Minas Gerais. Primary endpoints: Intraocular pressure and Ocular hyperemia. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
bimatoprost + brimonidine + timololtravoprostbimatoprosttimololdorzolamide
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on RBR-6kkmskk.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-6kkmskk.